Overview
The study aimed to evaluate the relationship between hepatitis B virus genotype and treatment response in children with chronic hepatitis B with specific treatment indications. This is a prospective cohort study, with a follow-up period of at least 12 months, conducted at Children's Hospital 1 and City Children's Hospital, Ho Chi Minh City, Vietnam. The patient's blood was taken to be tested for hepatitis B virus genotyping using Sanger sequencing at the Center for Molecular Biomedicine Ho Chi Minh City. The research hypothesis is that genotype is related to treatment response.
Eligibility
Inclusion Criteria:
- Children from 2 years old to under 16 years old are diagnosed with hepatitis B chronic disease AND
- HBsAg or HBV DNA: positive for at least six months AND
- Liver enzyme ALT: continuously increased by> 70 for male and > 50 for female (> 2 x ULN) AND
- The virus is proliferating: HBV DNA above 20,000 IU/mL (if HBeAg positive) OR HBV DNA above 2,000 IU/mL (if HBeAg negative) AND
- A parent or legal guardian of the pediatric patient obtains consent for them to participate in research.
Exclusion Criteria:
- HIV and hepatitis C co-infection
- Patients have other chronic liver disease (Wilson, autoimmune hepatitis)
- Patients are being treated with immunosuppressive drugs
- Psychomotor retardation, cerebral palsy, brain sequelae